The DNA methyltransferase DNMT1 and tyrosine-protein kinase KIT cooperatively promote resistance to 5-aza-2′-deoxycytidine (decitabine) and midostaurin (PKC412) in lung cancer cells

Fei Yan, Na Shen, Jiuxia Pang, Julian R Molina, Ping Yang, Shujun Liu

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Lung cancer cells are sensitive to 5-aza-2′-deoxycytidine (decitabine) or midostaurin (PKC412), because decitabine restores the expression of methylation-silenced tumor suppressor genes, whereas PKC412 inhibits hyperactive kinase signaling, which is essential for cancer cell growth. Here, we demonstrated that resistance to decitabine (decitabineR) or PKC412 (PKC412R) eventually results from simultaneously remethylated DNA and reactivated kinase cascades. Indeed, both decitabineRand PKC412R displayed the up-regulation of DNA methyltransferase DNMT1 and tyrosine-protein kinase KIT, the enhanced phosphorylation of KIT and its downstream effectors, and the increased global and gene-specific DNA methylation with the down-regulation of tumor suppressor gene epithelial cadherin CDH1. Interestingly, decitabineR and PKC412R had higher capability of colony formation and wound healing than parental cells in vitro, which were attributed to the hyperactive DNMT1 or KIT, because inactivation of KIT or DNMT1 reciprocally blocked decitabineR or PKC412R cell proliferation. Further, DNMT1 knockdown sensitized PKC412R cells to PKC412; conversely, KIT depletion synergized with decitabine in eliminating decitabineR. Importantly, when engrafted into nude mice, decitabineR and PKC412R had faster proliferation with stronger tumorigenicity that was caused by the reactivated KIT kinase signaling and further CDH1 silencing. These findings identify functional cross-talk between KIT and DNMT1 in the development of drug resistance, implying the reciprocal targeting of protein kinases and DNA methyltransferases as an essential strategy for durable responses in lung cancer.

Original languageEnglish (US)
Pages (from-to)18480-18494
Number of pages15
JournalJournal of Biological Chemistry
Volume290
Issue number30
DOIs
StatePublished - Jul 24 2015

Fingerprint

4'-N-benzoylstaurosporine
decitabine
Methyltransferases
Protein-Tyrosine Kinases
Lung Neoplasms
Cells
DNA
Phosphotransferases
Genes
Tumor Suppressor Genes
Tumors
Polynucleotide 5'-Hydroxyl-Kinase
Phosphorylation
Methylation
Cell proliferation
Cell growth
DNA Methylation
Cadherins
Drug Resistance
Nude Mice

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

@article{30013cdac203458fbd18b4696dc641aa,
title = "The DNA methyltransferase DNMT1 and tyrosine-protein kinase KIT cooperatively promote resistance to 5-aza-2′-deoxycytidine (decitabine) and midostaurin (PKC412) in lung cancer cells",
abstract = "Lung cancer cells are sensitive to 5-aza-2′-deoxycytidine (decitabine) or midostaurin (PKC412), because decitabine restores the expression of methylation-silenced tumor suppressor genes, whereas PKC412 inhibits hyperactive kinase signaling, which is essential for cancer cell growth. Here, we demonstrated that resistance to decitabine (decitabineR) or PKC412 (PKC412R) eventually results from simultaneously remethylated DNA and reactivated kinase cascades. Indeed, both decitabineRand PKC412R displayed the up-regulation of DNA methyltransferase DNMT1 and tyrosine-protein kinase KIT, the enhanced phosphorylation of KIT and its downstream effectors, and the increased global and gene-specific DNA methylation with the down-regulation of tumor suppressor gene epithelial cadherin CDH1. Interestingly, decitabineR and PKC412R had higher capability of colony formation and wound healing than parental cells in vitro, which were attributed to the hyperactive DNMT1 or KIT, because inactivation of KIT or DNMT1 reciprocally blocked decitabineR or PKC412R cell proliferation. Further, DNMT1 knockdown sensitized PKC412R cells to PKC412; conversely, KIT depletion synergized with decitabine in eliminating decitabineR. Importantly, when engrafted into nude mice, decitabineR and PKC412R had faster proliferation with stronger tumorigenicity that was caused by the reactivated KIT kinase signaling and further CDH1 silencing. These findings identify functional cross-talk between KIT and DNMT1 in the development of drug resistance, implying the reciprocal targeting of protein kinases and DNA methyltransferases as an essential strategy for durable responses in lung cancer.",
author = "Fei Yan and Na Shen and Jiuxia Pang and Molina, {Julian R} and Ping Yang and Shujun Liu",
year = "2015",
month = "7",
day = "24",
doi = "10.1074/jbc.M114.633693",
language = "English (US)",
volume = "290",
pages = "18480--18494",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "30",

}

TY - JOUR

T1 - The DNA methyltransferase DNMT1 and tyrosine-protein kinase KIT cooperatively promote resistance to 5-aza-2′-deoxycytidine (decitabine) and midostaurin (PKC412) in lung cancer cells

AU - Yan, Fei

AU - Shen, Na

AU - Pang, Jiuxia

AU - Molina, Julian R

AU - Yang, Ping

AU - Liu, Shujun

PY - 2015/7/24

Y1 - 2015/7/24

N2 - Lung cancer cells are sensitive to 5-aza-2′-deoxycytidine (decitabine) or midostaurin (PKC412), because decitabine restores the expression of methylation-silenced tumor suppressor genes, whereas PKC412 inhibits hyperactive kinase signaling, which is essential for cancer cell growth. Here, we demonstrated that resistance to decitabine (decitabineR) or PKC412 (PKC412R) eventually results from simultaneously remethylated DNA and reactivated kinase cascades. Indeed, both decitabineRand PKC412R displayed the up-regulation of DNA methyltransferase DNMT1 and tyrosine-protein kinase KIT, the enhanced phosphorylation of KIT and its downstream effectors, and the increased global and gene-specific DNA methylation with the down-regulation of tumor suppressor gene epithelial cadherin CDH1. Interestingly, decitabineR and PKC412R had higher capability of colony formation and wound healing than parental cells in vitro, which were attributed to the hyperactive DNMT1 or KIT, because inactivation of KIT or DNMT1 reciprocally blocked decitabineR or PKC412R cell proliferation. Further, DNMT1 knockdown sensitized PKC412R cells to PKC412; conversely, KIT depletion synergized with decitabine in eliminating decitabineR. Importantly, when engrafted into nude mice, decitabineR and PKC412R had faster proliferation with stronger tumorigenicity that was caused by the reactivated KIT kinase signaling and further CDH1 silencing. These findings identify functional cross-talk between KIT and DNMT1 in the development of drug resistance, implying the reciprocal targeting of protein kinases and DNA methyltransferases as an essential strategy for durable responses in lung cancer.

AB - Lung cancer cells are sensitive to 5-aza-2′-deoxycytidine (decitabine) or midostaurin (PKC412), because decitabine restores the expression of methylation-silenced tumor suppressor genes, whereas PKC412 inhibits hyperactive kinase signaling, which is essential for cancer cell growth. Here, we demonstrated that resistance to decitabine (decitabineR) or PKC412 (PKC412R) eventually results from simultaneously remethylated DNA and reactivated kinase cascades. Indeed, both decitabineRand PKC412R displayed the up-regulation of DNA methyltransferase DNMT1 and tyrosine-protein kinase KIT, the enhanced phosphorylation of KIT and its downstream effectors, and the increased global and gene-specific DNA methylation with the down-regulation of tumor suppressor gene epithelial cadherin CDH1. Interestingly, decitabineR and PKC412R had higher capability of colony formation and wound healing than parental cells in vitro, which were attributed to the hyperactive DNMT1 or KIT, because inactivation of KIT or DNMT1 reciprocally blocked decitabineR or PKC412R cell proliferation. Further, DNMT1 knockdown sensitized PKC412R cells to PKC412; conversely, KIT depletion synergized with decitabine in eliminating decitabineR. Importantly, when engrafted into nude mice, decitabineR and PKC412R had faster proliferation with stronger tumorigenicity that was caused by the reactivated KIT kinase signaling and further CDH1 silencing. These findings identify functional cross-talk between KIT and DNMT1 in the development of drug resistance, implying the reciprocal targeting of protein kinases and DNA methyltransferases as an essential strategy for durable responses in lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=84937721119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937721119&partnerID=8YFLogxK

U2 - 10.1074/jbc.M114.633693

DO - 10.1074/jbc.M114.633693

M3 - Article

VL - 290

SP - 18480

EP - 18494

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 30

ER -